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Abstract
Lafora disease is an autosomal recessive form of progressive myoclonus epilepsy with no effective therapy. Although the
outcome is always unfavorable, onset of symptoms and progression of the disease may vary. We aimed to identify modifier
genes that may contribute to the clinical course of Lafora disease patients with EPM2A or EPM2B mutations. We established
a list of 43 genes coding for proteins related to laforin/malin function and/or glycogen metabolism and tested common
polymorphisms for possible associations with phenotypic differences using a collection of Lafora disease families. Genotype
and haplotype analysis showed that PPP1R3C may be associated with a slow progression of the disease. The PPP1R3C gene
encodes protein targeting to glycogen (PTG). Glycogen targeting subunits play a major role in recruiting type 1 protein
phosphatase (PP1) to glycogen-enriched cell compartments and in increasing the specific activity of PP1 toward specific
glycogenic substrates (glycogen synthase and glycogen phosphorylase). Here, we report a new mutation (c.746A.G,
N249S) in the PPP1R3C gene that results in a decreased capacity to induce glycogen synthesis and a reduced interaction
with glycogen phosphorylase and laforin, supporting a key role of this mutation in the glycogenic activity of PTG. This
variant was found in one of two affected siblings of a Lafora disease family characterized by a remarkable mild course. Our
findings suggest that variations in PTG may condition the course of Lafora disease and establish PTG as a potential target for
pharmacogenetic and therapeutic approaches.
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Introduction
Lafora disease (LD; MIM#254780) is an autosomal recessive
form of progressive myoclonus epilepsy that typically manifests
during adolescence and is characterized by epilepsy, progressive
neurologic deterioration, myoclonus and epileptic seizures. The
disease leads to a vegetative state and death, usually within less
than a decade from the onset of the initial symptoms [1]. The
hallmark of LD is the presence of polyglucosan intracellular
bodies, first described by Lafora and Glueck in 1911 [2]. These
inclusions have been found in many tissues, including brain, spinal
cord, liver, skin, skeletal muscle, heart and retina [3].
Two genes have been associated with LD: EPM2A [4–5] and
EPM2B [6]. EPM2A (MIM#607566) is a four-exon gene which
encodes a protein known as laforin. Initially, laforin was partially
characterized and described as a dual-specificity phosphatase
[4–5]. Subsequently, the complete coding human sequence of the
gene including the ATG initiation codon region was reported [7].
The complete protein shows an amino-terminal carbohydrate
binding module (CBM) that is critical for association with glycogen
both in vitro and in vivo [8]. EPM2B (MIM#608072) is a single-
exon gene which codes for an E3-ubiquitin ligase, known as malin,
that contains a RING finger domain and six NHL-domains
involved in protein-protein interactions [7,9]. Malin interacts with
and ubiquitinates laforin, leading to its degradation [9].
Laforin and malin appear to be part of a multiprotein complex
that may be associated with the formation of intracellular glycogen
particles. Within this complex, laforin interacts with protein
targeting to glycogen known as PTG (Gene symbol PPP1R3C,
MIM#602999), one of the glycogen targeting regulatory subunits
of protein phoshatase 1 (PP1) [10]. Recently, it has been shown
that the glycogenic activity of PTG is down-regulated by the
laforin-malin complex by inducing protesome-dependent degra-
dation [11–13]. However, the absence of malin in mice does not
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21294affect the levels of glycogen synthase, PTG or debranching enzyme
[14].
Lafora disease patients show variability in the age and symptoms
at onset, as well as in the duration of disease progression, even
among affected siblings with the same mutation [15–19]. The
striking finding of hepatic disease as the first manifestation of LD in
one of two affected siblings, suggests that modifier genes must
condition the clinical expression of the disease [20].
To determine if genes involved in the regulation of EPM2A and
EPM2B can modify the onset and progression of the disease, we
screened a total of 43 genes coding for proteins related to laforin/
malin function and/or glycogen metabolism in a collection of LD
families that showed intrafamilial phenotypic differences. We
found two heterozygous variations in the PPP1R3C gene. In this
work we tested the significance of these variations on the
glycogenic capacity of human PTG and their possible role in an
exceptionally mild form of the disease.
Results
Haplotype analysis reveals PPP1R3C as a candidate gene
that modifies disease progression
We evaluated if LD patients with intrafamilial phenotypic
differences (age at onset or disease progression) presented distinct
haplotypes for each of the selected 43 gene loci related to laforin/
malin function or to glycogen metabolism (see Materials and Methods).
Genotyping analysis showed a possible association of PPP1R3C
with a slow progression of the disease. Since PTG, the gene
product of PPP1R3C, has previously been shown to interact
directly with laforin [10], we focused our attention on this gene.
Analysis of PPP1R3C mutations
Sequencing analysis of the two exons, the promoter region and
untranslated regions of PPP1R3C was carried out in a total of 23
LD patients.
We identified two distinct heterozygous DNA transitions in our
patients: one in the coding sequence and one in the 59untranslated
region of PPP1R3C (Figure 1). Variations were named based on
mRNA reference sequence NM_005398 and protein sequence
NP_005389. The variation in the coding region was an amino acid
substitution of asparagine for serine at position 249 (N249S,
c.746A.G). This residue is completely conserved throughout
evolution (Figure 2). The other transition (250T.C) was found in
the promoter region and matched with a known SNP
(rs62620038). No mutations segregating with the phenotype were
identified in the 39-untranslated region. The N249S variant was
found in patient 127-3, who also carried two mutations in EPM2B,
D146N and S339fsX351. The 250T.C variant was found in
patient 111-3 who had a homozygous deletion in EPM2A
(Ex1_33bpdel, R31_R41del).
Subsequent TaqMan probe assays were designed in order to test
these variants in an additional sample of 30 LD affected individuals
and in Spanish (n=94) and Italian (n=119) control populations.
The 250T.C variant was present in eight control but c.746A.G
(N249S) was absent in all the tested controls and in dbSNP.
Clinical findings
Individual 127-3 is a 43 year old Italian woman. Although she
had two isolated tonic-clonic seizures at ages 5 and 6 years, she
was in good health until the age of 22, when she had a new tonic-
clonic seizure and reported onset of myoclonic jerks. Since then,
the neurological picture progressed slowly. An EEG and a skin
biopsy were consistent with the diagnosis of LD. Presently, she has
resting and action myoclonus, mental deterioration and cerebellar
signs. However, she is still almost completely autonomous.
Individual 111-3 was a Spanish woman last seen at the age of
19 years with seizure onset at the age of 14 years, (generalyzed
tonic-clonic seizure). She presented a severe evolution of the
disease with absence seizures, myoclonic jerks and mental
deterioration. Her EEG and skin biopsy were consistent with the
diagnosis of LD.
PTG carrying the N249S mutation shows a decreased
interaction with some PTG interacting partners
To check whether the N294S mutation affected the interaction
of PTG with some of its partners (Figure 2), we performed a yeast
two-hybrid analysis with protein phosphatase 1 (PP1), glycogen
phosphorylase (GPh), AMP-activated protein kinase subunit b2
(AMPKb2) and laforin. As shown in Figure 3, the N294S mutant
form interacted with PP1 and AMPKß2 with a similar strength as
the wild type. However, the interaction with laforin and glycogen
phosphorylase was significantly reduced. Western blot analysis
indicated that the observed reduction in interaction was not due to
reduced levels of the N249S mutant (Figure 3).
N249S reduces glycogen synthesis induction capacity of
PTG
In order to establish whether the N249S variation affects PTG
function, we analyzed its capacity to modulate the PTG-induced
accumulation of glycogen. Glycogen synthesis is a highly regulated
process that depends on the activity of glycogen synthase (GS).
This enzyme exists in two forms, an inactive extensively
phosphorylated form (pGS) and an active dephosphorylated form.
We aimed to determine whether the N249S-PTG mutant was
active in dephosphorylating pGS. We transfected HEK293 cells
with plasmids expressing wild type and the N249S mutant form of
PTG and analyzed the phosphorylation status of GS by Western
blotting. The expression of wild type PTG induced the appearance
of dephosphorylated forms of GS (faster migrating bands), whereas
the expression of the N249S mutant was not able to produce
significant amounts of dephosphorylated GS (Figure 4A). We then
analyzed the glycogenic properties of wild type and mutant forms.
Consistent with previous reports [12,21,22] the expression of wild
type PTG in HEK293 cells induced the accumulation of glycogen
in these cells. However, the N249S-PTG mutant could only
partially induce the accumulation of glycogen (Figure 4B).
Moreover, we have recently described that the glycogenic activity
of PTG is downregulated by the laforin-malin complex [12].
Consistent with this result, we observed a reduction of 5762% in
the glycogenic activity of wild type PTG when co-expressed with
laforin and malin (Figure 4B). The glycogenic activity of the
N249S-PTG mutant form was also reduced (4469%) by the co-
expression of laforin and malin (Figure 4B), indicating that this
mutated form could still be a target of laforin-malin action.
Perhaps this is the consequence of the partial reduction in the
laforin- PTG interaction observed in the N249S mutant (4468%;
Fig. 3).
N249S ameliorates the phenotype of the absence of
laforin
To determine whether N249S-PTG mutant form could modify
the glycogen accumulation phenotype in a neuronal cell line, we
reduced the expression of laforin in a SH-SY5Y human
neuroblastoma cells by shRNA (Figure 5A) and transfected these
cells with either wild type or N249S-PTG mutant forms. We
observed that only in the absence of laforin, was PTG wild type
PTG Modifies the Course of Lafora Disease
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21294able to induce the accumulation of glycogen in these cells,
indicating that in control cells laforin is a strong regulator of PTG
activity (Figure 5B). In control cells we also observed a higher
accumulation of the N249S mutant form, suggesting a lower
capacity of the endogenous laforin to regulate the levels of this
protein (Figure 5B). However, in laforin depleted cells, although
the expression of N249S-PTG was similar to wild type, it
promoted a lower accumulation of glycogen (Figure 5B). These
results indicated that at least at the level of glycogen, the presence
of the N249S variant ameliorated the phenotype produced by the
absence of laforin.
SNP rs62620038 influences gene reporter activity
The PPP1R3C 59-UTR SNP has previously been denoted as
rs62620038. However, there are no studies concerning the
potential effect of this SNP on PPP1R3C expression. To analyze
this point, an 896 bp 59-UTR fragment was cloned into pGL3
luciferase reporter plasmid for transient transfection experiments
in PC12 and EOMA cells (Figure 6A and 6B). Moreover, we
constructed a 182 promoter fragment that was also analyzed
(Figure 6A).
We observed that this short construct promoted the expression
of the reporter gene at a similar extent as the longer promoter
fragment, indicating that all regulatory elements of the PPP1R3C
gene promoter were contained in the first 182 bp.
Mutated constructs carrying the 250T.C transition showed a
statistically significant lower luciferase activity (24%) vs the
corresponding wild type promoters (Figure 6B).
No statistically significant different promoter activity was
conferred by constructs containing the 2895 or 2181 bp of the
upstream sequence (Figure 6B). These results pointed out that the
necessary positive regulatory elements for basal transcription
reside in the most proximal region of the upstream sequence.
Discussion
Lafora disease is an autosomal reccessive and fatal form of
epilepsy characterized by the presence of cytoplasmatic aggre-
gates of water-insoluble, poorly branched polyglucosans. These
accumulate in the central and peripheral nervous system, among
other tissues [23,24]. However, it is unclear whether the
accumulation of Lafora bodies is the cause of the disease or
whether Lafora bodies are secondary determinants of a primarily
established metabolic alteration [25]. Glycogen homeostasis
depends mainly on the activity of enzymes involved in its
synthesis (glycogen synthase or GS) and degradation (glycogen
phosphorylase or GPh) through mechanisms involving phosphor-
ylation [26,27]. Type 1 protein phosphatase (PP1) dephosphor-
ylates and activates GS and dephosphorylates and inactivates
GPh and glycogen phosphorylase kinase (GPK) resulting in
glycogen accumulation [26,27]. The action of PP1 is controlled
by several glycogen targeting subunits. PTG facilitates binding of
PP1 to glycogen and acts as a molecular scaffold assembling PP1
with GS, GPh, and GPK at intracellular glycogen particles [11].
Thus, PTG modulates glycogen accumulation by bringing PP1 to
GS for its activation [28].
Figure 1. Mutational analysis of PPP1R3C. (A) Electropherograms show the two containing-variation regions in control (top) and affected
individuals (bottom). Nucleotides that change are indicated. B) Schematic drawing of the genomic structure of PPP1R3C. Position of the variations
found in Lafora disease patients is shown.
doi:10.1371/journal.pone.0021294.g001
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described). One of these mutations replaces asparagine for serine
at position 249 (N249S) and shows significant functional
implications in glycogen metabolism. Asparagine 249 is a highly
conserved amino acid located at the C-terminus of the protein and
is surrounded by two aspartic acid residues that are essential for
PTG activity since they are involved in the interaction of PTG
with glycogenic substrates such as GS and GPh [27]. We provide
Figure 2. Schematic drawing of PTG domain structure and multiple alignments of human PTG amino acid sequence. Multiple
alignments of the motif shared by substrate binding domain of human PTG amino acid sequence and paralogues and homologues from various
species are shown and identities are shadowed. The mutated asparagine residue (position 249 in the protein) is indicated with a vertical box.
Asterisks mark esential aspartic residues that surround asparagine. Abbreviations are as follows: PBS, PP1 binding site; CBM21, carbohydrate binding
module type-21; GBS, glycogen binding site; SBS, substrate binding site; PP1, protein phosphatase 1; AMPK, AMP-activated protein kinase; GPh,
glycogen phosphorylase; GS, glycogen synthase; GPK, glycogen phosphorylase kinase.
doi:10.1371/journal.pone.0021294.g002
PTG Modifies the Course of Lafora Disease
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21294evidence that this mutant form (N249S-PTG) results in a reduction of
interaction with its partners GPh and laforin, and a decreased
capacity to induce glycogen synthesis. In patients with EPM2A and
EPM2B mutations loss-of-function of the laforin/malin complex
results in PTG overexpression leading to the activation of GS and the
accumulation of glycogen-associated PP1 [28]. The N249S-PTG
Figure 3. Yeast two-hybrid interaction assays of PTG with different proteins. Yeast CTY10.5d strain was transformed with plasmids pACT2
(empty plasmid), pACT2- PTG (wt), or pACT2-N249S-PTG (N249S) and co-transformed with plasmids pBTM-PP1a (LexA-PP1), pBTM-AMPKb2 (LexA-
AMPKß2), pEG202-laforin (LexA-laforin) and pEF202-RABPYGM (LexA-GPh). Protein interaction was estimated by measuring the b-Galactosidase
activity in permeabilized yeast cells and expressed in Miller units. Abbreviations: PP1a, protein phosphatase 1; AMPKb2, AMP-activated protein kinase
subunit b2; GPh, glycogen phosphorylase. When indicated, crude extracts (25 mg) from two independent transformants were analyzed by western
blotting using anti-LexA and ant-HA antibodies.
doi:10.1371/journal.pone.0021294.g003
Figure 4. The presence of N249S in PTG reduces glycogen synthesis by blocking its capacity to activate GS. (A) Crude extracts from
homogenates of cultured HEK293 cells transfected with pCMV-HA empty plasmid (none) or plasmids expressing wild type (WT) and mutated HA- PTG
(N249S) were obtained and analyzed by Western blotting using anti-GS and anti- PTG. Actin was used as a control for gel loading. (B) HEK293 cells were co-
transfected or not with plasmids pCMV-myc-laforin/pcDNA-HA-malin and with pCMV-HA (empty plasmid; none) or plasmids expressing wild type (WT) or
mutated HA- PTG (N249S). Eighteenhours after the transfection, the amount ofaccumulated glycogenwasmeasured as described in Materials and Methods.
doi:10.1371/journal.pone.0021294.g004
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the up-regulation of glycogen synthesis observed in LD, possibly
resulting in an amelioration of LD symptoms. We also provide
evidence that this reduction in the glycogenic capacity of the N249S-
PTG mutant form is due to its lower capacity to dephosphorylate and
activate GS (Figure 4A).
The relevance of the functional studies presented here
contrasts with the finding that only one of the affected siblings
of family 127 carried the N249S variant in PPP1R3C. The patient
who does not carry the mutation is, as his sib, almost completely
autonomous but has clusters of diffuse myoclonic jerks on
awakening. Both siblings carry the same mutations in EPM2B
and mutations in this gene have been associated with a milder
clinical course of the disease compared with EPM2A patients
[18]. Moreover, it is remarkable that the patient with the PTG
N249S mutation does not express other metabolic alterations in
tissues where PTG is functional (liver, skeletal muscle, adipose
tissue), indicating that other glycogen targeting subunits could
compensate this deficiency.
Sequencing analysis of PPP1R3C in our patients revealed
another variant located in the 59-untranslated region that had
been previously reported as a SNP (rs62620038). Deletion analysis
in the upstream region of PPP1R3C showed that the elements
responsible for basal promoter activity reside in the region
proximal to the transcription initiation site, just where this SNP
lies. Although this SNP was present in one LD patient and eight
control individuals, luciferase reporter assays showed that this
change affects human PPP1R3C promoter activity resulting in a
mild decrease in gene expression. Perhaps, this may be the reason
why the LD patient carrying this polymorphism does not present a
modification in disease progression.
In conclusion, we identified a new variation in PTG that might
contribute to ameliorate the symptoms of LD. However, other
modifier factors may be involved in the clinical heterogeneity
observed in Lafora disease. Our results suggest that PTG should
be further studied as a potential pharmacogenetic target in LD.
Materials and Methods
Patients and samples
We studied 23 patients from 10 families diagnosed with LD.
Diagnosis was based on the presenceof epilepsy, myoclonus, rapidly
progressive neurologic deterioration, and slow background with
polyspike-wave complexes on EEG [1,29]. A skin, muscle or liver
biopsy was also required to confirm the presence of PAS-positive
intracellular inclusions (Lafora bodies). Blood tests were reviewed
when available in order to including cell blood count and complete
biochemical panel to exclude liver, kidney or blood diseases.
All patients, except two, presented mutations in EPM2A or
EPM2B.
Control subjects from Spanish and Italian populations were
included in this study.
Blood was collected from patients and their relatives after
informed consent. DNA samples were obtained from peripheral
blood lymphocytes using standard methods. The study was
approved by the Ethics Committee of the Fundacio ´n Jime ´nez Dı ´az.
Genes selection and Genotyping
We selected 43 genes potentially involved in the regulation of
laforin/malin function and/or glycogen metabolism. EPM2A and
EPM2B were also included as control of association. An
interaction network showing relationship among these genes is
Figure 5. The N249S mutation in PTG diminishes the amount of glycogen accumulated in laforin-depleted cells. A) Human
neuroblastoma SH-SY5Y cells were transfected with plasmid pSUPER-laf to deplete the levels of laforin. Crude extracts from these cells were analyzed
by western blotting using anti-laforin and anti-actin antibodies. B) SH-SY5Y cells depleted (sh-laforin) or not (control) of laforin were transfected with
plasmids pCMV-HA (empty plasmid; none) or plasmids expressing wild type (WT) or mutated HA- PTG (N249S). Eighteen hours after the transfection,
the amount of accumulated glycogen was measured as described in Materials and Methods. The dotted line represent the levels of glycogen in
control conditions. Crude extracts from the same cells were analyzed by western blotting using anti-HA and anti-actin antibodies.
doi:10.1371/journal.pone.0021294.g005
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performed using the online database resource Search Tool for the
Retrieval of Interacting Genes (STRING, version 8.3). Interac-
tions in STRING are provided with a confidence score and
stronger associations are represented by thicker lines.
Genotyping was performed by analyzing polymorphic markers:
39 tagging single-nucleotide polymorphisms (tSNPs) from the
HapMap database for population CEU and 95 microsatellites that
included all gene loci linked to the selected genes. Haplotypes were
determined by segregation analysis in families.
Common SNPs were chosen using Tagger-Pairwise algorithm
with a r
2.0.8 and a minor allele frequency (MAF).0.2.
We assessed tSNPs by using TaqManH SNP genotyping assays
(Applied Biosystems, Foster City, CA, USA) and the 7000 Real-
Time PCR System (Applied Biosystems). Genotyping success rate
was 92.31% and the consensus rate was 100% (based on 100%
duplicate genotypes).
Microsatellite sequences were amplified using PCR with a specific
fluorescence- labelled primer. PCR products were run in an ABI
Prism 3130 genetic analyzer (Applied Biosystems) and analyzed with
the GeneMapper v3.5 software package (Applied Biosystems).
Mutation analysis
PPP1R3C sequencing was performed from PCR-amplified
genomic DNA fragments in both orientations. Sequence analysis
covered all exonic sequences, exon/intron boundaries, and the
regulatory 59- and 39-region and was performed by using dye
terminator cycle sequencing kit (Applied Biosystems) with a ABI
3130 sequencer (Applied Biosystems).
Cell culture and western blot
Human embryonic kidney (HEK293) and neuroblastoma (SH-
SY5Y) cells were grown in DMEM (Lonza, Basel, Switzerland)
and DMEM F12 (Lonza) respectively, supplemented with 100
units/ml penicillin, 100 mg/ml streptomycin, 2 mM glutamine (all
from Sigma-Aldrich, USA) and 10% inactivated fetal bovine
serum (FBS, GIBCO) at 37uC in an atmosphere of humidified 5%
CO2. The day before transfection, 1.5610
6 cells were plated onto
60 mm-diameter culture dishes. Cells were transfected with 1 mg
of each plasmid using Lipofectamine 2000 (Invitrogen-Life
Technologies, Inc, Carlsbad, CA,USA). After twenty-four hours,
the cells were scraped on ice in lysis buffer [10 mM TrisHCl pH 8;
150 mM NaCl, 15 mM EDTA; 0.6 M sucrose, 0.5% nonidet P-40
(NP-40), complete protease inhibitor cocktail (Roche Diagnostics,
Meylan, France) and 1 mM PMSF, 50 mM NaF and 5 mM
Na2P2O7] and lysed by repeated passage through a 25-gauge
needle. Twenty-five micrograms of total protein, from the soluble
fraction of cell lysates, were analyzed by SDS-PAGE and Western
blotting using appropriate antibodies: mouse monoclonal anti-
laforin [12], rabbit polyclonal anti- PTG (raised against the
synthetic peptide (GPYDEFQRRHFVNK) corresponding to
amino acids 16–29 of the human PTG) [28], mouse monoclonal
anti-GS (Chemicon, Millipore, Billerica, MA, USA), mouse
monoclonal anti-HA (Sigma) or rabbit polyclonal anti-actin
(Sigma).
Site-directed Mutagenesis
Site-directed mutagenesis of the PTG construct was performed
using the QuikChange kit (Stratagene, La Jolla, CA, USA) and the
Figure 6. Impact of the 250T.C variant in pGL3 basic-derived constructs. A) Partial structures of constructs used in reporter assays. B) Gene
reporter assays in PC12 and EOMA cells. Cells were transiently co-transfected with the reporter constructs containing the rs62620038 (position 250)
variant or empty vector, as indicated. Each bar represents the average fold-induction relative to the empty vector.
doi:10.1371/journal.pone.0021294.g006
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CAAGTCTTTTGGGACAACAGTGATGGTCAGAATTATA-
GAATTGTT -39, reverse, 59- AATTCTATAATTCTGACCAT-
CACTGTTGTCCCAAAAGACTTGCCCATT -39, and for
b) 59-UTR: forward, 59- CTGTGGTTCGAATCTGTGCAGG-
CAGCG-39, reverse, 59-CGCTGCCTGCACAGATTCGAAC-
CACAG-39.
Mutations and construct fidelity were confirmed by DNA
sequencing.
Plasmids
Plasmid pACT2- PTG contained the human full length PTG
open reading frame [28]. Plasmid pACT2-PTG-N249S was
generated by subcloning the mutated PTG fragment (described
below) into pACT2 vector. A SfiI/BglII fragment from pACT2-
PTG plasmid was subcloned into vector pCMV-HA (Clontech) in
order to obtain wild type plasmid (pCMV-HA- PTG) and mutant
plasmid (pCMV-HA-PTG-N249S).
Plasmid pEG202-RABPYGM (GPh), containing the rabbit full
length muscular isoform of glycogen phosphorylase was obtained
by subcloning a fragment from plasmid pEGFP-C1-MGP into
pEG202. Other plasmids used in this study were pBTM-PP1a,
pBTM-AMPKm2, pEG202-laforin, pCMV-myc-laforin and
pcDNA-HA-malin [30].
Laforin siRNA silencing
The mammalian expression vector pSUPER.neo.GFP (Oli-
goengine) was used for expression of laforin-specific shRNA in
human neuroblastoma SH-SY5Y cells. Sense and anti-sense
oligonucleotides corresponding to nucleotides 872–891 of human
EPM2A cDNA (GenBank accession no. NM_005670) were
annealed and subcloned into pSUPER.neo.GFP vector, resulting
in plasmid pSUPER-laf [30].
Yeast two hybrid analysis
Yeast CTY10.5d strain was co-transformed with combinations
of pACT2- PTG (wild type or N249S) and the indicated plasmids.
Transformants were grown in selective SD medium and ß-
galactosidase activity was assayed in permeabilized cells and
expressed in Miller Units [12].
Glycogen determination
Glycogen determination in transfected cells was carried out as
described by Vernia et al. [28].
Luciferase constructs
Analysis of PPP1R3C 59-UTR was performed by insertion of a
890 pb fragment of the promoter region into vector pGL3 basic
(Promega) using NcoI and HindII sites. This fragment was
amplified by PCR using human genomic DNA as a template and
appropriated primers. The 59 oligo used was 59-AAGCTTCTGC-
CAAAGGACGTCAGAATTG-39 (HindII site underlined) and
the 39 oligo used was 59-CCATGGTTAGGCAGAGAGGC-
GGCGGA-39 (NcoI site underlined). The mutant plasmid was
generated from the pGL3-896wt by site-directed mutagenesis.
Plasmids with a 182 pb promoter were generated by digestion of
pGL3-896wt and pGL3-896mut with XhoI and relegation and
were subsequently denoted as pGL3-182wt and pGL3-182mut,
respectively. The host strain for plasmid construction was
Escherichia coli DH5a.
Dual luciferase reporter assays
PC12 (derived from a pheochromocytoma of the rat adrenal
medulla) and EOMA cells (derived from a mixed hemangioendo-
thelioma present in an adult mouse) were cultured in 6-well plates
and transfected at 50–60% confluence with 20 mg of individual
reporter gene construct and Renilla/luciferase (100:1 ratio) with
Lipofectamine 2000 (Invitrogene). The total amount of DNA in
each experiment was kept constant by using vector DNA controls.
After forty-eight hours, cells were harvested in Passive Lysis Buffer
(PLB, Promega), subjected to two freeze-thaw cycles and then
precleared by centrifugation at 14,0006g for 1 min. Luciferase
assays were performed in the supernatants using the Dual-
Luciferase Reporter Assay System (Promega) according to the
manufacturer’s instructions. Luminiscence was measured with a
Infinite 200 Nanoquant luminometer (Tecan Group, LTD).
Values of firefly luciferase activity were normalized by those of
Renilla luciferase activity.
Statistical data analysis
Data are expressed as mean 6 standard deviation (SD).
Statistical evaluations were made by two-tailed Student’s t test
and one way ANOVA followed by the Student-Newman–Keuls
multiple test as a post-hoc evaluation. Significance was ascribed at
*p,0.05, **p,0.01 and *** p,0.001, as indicated in each case.
Supporting Information
Figure S1 Protein-protein interaction network visual-
ized by STRING. Confidence view of the network is shown for
proteins potentially involved in the regulation of laforin/malin
function and/or glycogen metabolism. Each protein is represented
by circles. The color saturation of the edges represents the
confidence score of the association. Stronger associations are
represented by thicker lines.
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